HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: An analysis from the JUPITER trial

The Lancet

Volumn 376, Issue 9738, 2010, Pages 333-339

  Ridker, Paul M ^a   Genest, Jacques ^b   Boekholdt, S Matthijs ^e   Libby, Peter ^a   Gotto, Antonio M ^c   Nordestgaard, Børge G ^d   Mora, Samia ^a   MacFadyen, Jean G ^a   Glynn, Robert J ^a   Kastelein, John J P ^e  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOUBLE BLIND PROCEDURE; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; METABOLIC PARAMETERS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 77955712458     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60713-1     Document Type: Article

References (25)

1. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
2. FM Sacks, MA Pfeffer, LA Moye for the Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009
3. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
4. J Shepherd, SM Cobbe, I Ford for the West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
5. JR Downs, M Clearfield, S Weis for the AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
6. PM Ridker, E Danielson, FA Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
7. T Gordon, WP Castelli, MC Hjortland, WB Kannel, TR Dawber High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study Am J Med 62 1977 707 714
8. PH Frost, BR Davis, AJ Burlando Serum lipids and incidence of coronary heart disease. Findings from the Systolic Hypertension in the Elderly Program (SHEP) Circulation 94 1996 2381 2388
9. B Lamarche, JP Despres, S Moorjani, B Cantin, GR Dagenais, PJ Lupien Triglycerides and HDL-cholesterol as risk factors for ischemic heart disease. Results from the Quebec cardiovascular study Atherosclerosis 119 1996 235 245
10. AR Sharrett, CM Ballantyne, SA Coady Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study Circulation 104 2001 1108 1113
11. 100, standard lipid measures, lipid ratios and CRP as risk factors for cardiovascular disease in women JAMA 294 2005 326 333
12. EM deGoma, NJ Leeper, PA Heidenreich Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol J Am Coll Cardiol 51 2008 49 55
13. FM Sacks, AM Tonkin, J Shepherd Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project Circulation 102 2000 1893 1900
14. P Barter, AM Gotto, JC LaRosa HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events N Engl J Med 357 2007 1301 1310
15. KK Ray, CP Cannon, R Cairns, DA Morrow, PM Ridker, E Braunwald Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22 Arterioscler Thromb Vasc Biol 29 2009 424 430
16. RJ Glynn, E Danielson, FA Fonseca A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med 360 2009 1851 1861
17. PM Ridker, E Danielson, FA Fonseca Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 2009 1175 1182
18. AM Gotto, E Whitney, EA Stein Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) Circulation 101 2000 477 484
19. LA Frassetto, M Schloetter, M Mietus-Synder, RC Morris Jr, A Sebastian Metabolic and physiologic improvements from consuming a paleolithic, hunter-gatherer type diet Eur J Clin Nutr 63 2009 947 955
20. EM deGoma, RL deGoma, DJ Rader Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches J Am Coll Cardiol 51 2008 2199 2211
21. PJ Barter, M Caulfield, M Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
22. SE Nissen, JC Tardif, SJ Nicholls Effect of torcetrapib on the progression of coronary atherosclerosis N Engl J Med 356 2007 1304 1316
23. JJ Kastelein, SI van Leuven, L Burgess Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia N Engl J Med 356 2007 1620 1630
24. AR Tall, L Yvan-Charvet, N Wang The failure of torcetrapib: was it the molecule or the mechanism? Arterioscler Thromb Vasc Biol 27 2007 257 260
25. M Briel, I Ferreira-Gonzalez, JJ You Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and m0ession analysis BMJ 338 2009 b92